Franklin Resources Inc. reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 266,848 shares of the medical research company’s stock after selling 2,493 shares during the period. Franklin Resources Inc. owned 0.07% of Thermo Fisher Scientific worth $50,669,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. Icon Wealth Partners LLC bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $105,000. Bank of Nova Scotia Trust Co. bought a new position in Thermo Fisher Scientific during the third quarter worth about $106,000. Keeler Thomas Management LLC bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $106,000. SeaCrest Wealth Management LLC bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $195,000. Finally, Csenge Advisory Group bought a new position in Thermo Fisher Scientific during the third quarter worth about $201,000. Institutional investors and hedge funds own 87.63% of the company’s stock.
Shares of Thermo Fisher Scientific stock opened at $210.44 on Monday. Thermo Fisher Scientific Inc. has a 12 month low of $151.74 and a 12 month high of $226.44. The stock has a market capitalization of $84,551.45, a PE ratio of 22.20, a price-to-earnings-growth ratio of 1.54 and a beta of 1.15. The company has a quick ratio of 0.92, a current ratio of 1.34 and a debt-to-equity ratio of 0.74.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter last year, the business posted $2.41 EPS. The company’s revenue for the quarter was up 22.1% on a year-over-year basis. equities research analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be paid a $0.17 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 12.14%.
Several research firms have weighed in on TMO. Leerink Swann reiterated an “outperform” rating and set a $200.00 target price (down from $216.00) on shares of Thermo Fisher Scientific in a report on Monday, December 4th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. BTIG Research began coverage on Thermo Fisher Scientific in a report on Friday, January 5th. They set a “buy” rating and a $230.00 target price on the stock. Zacks Investment Research upgraded Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Finally, Barclays lifted their target price on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Two analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $220.50.
In related news, SVP Gregory J. Herrema sold 33,327 shares of Thermo Fisher Scientific stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $219.70, for a total value of $7,321,941.90. Following the sale, the senior vice president now owns 60,471 shares of the company’s stock, valued at $13,285,478.70. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William G. Parrett sold 1,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $209.80, for a total value of $209,800.00. The disclosure for this sale can be found here. Insiders sold a total of 48,827 shares of company stock worth $10,606,272 in the last three months. Company insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.